Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma.
Rahul KumarKyle S SmithMaximilian DengColt TerhuneGiles W RobinsonBrent A OrrAnthony Pak-Yin LiuTong LinCatherine A BillupsMurali ChintagumpalaDaniel C BowersTimothy E HassallJordan R HansfordDong-Anh Khuong-QuangJohn R CrawfordAnne E BendelSridharan GururanganKristin M SchroederEric BouffetUte BartelsMichael J FisherRichard CohnSonia PartapStewart J KellieGeoffrey McCowageArnold C PaulinoStefan RutkowskiGudrun FleischhackGirish DhallLaura J KlesseSarah E S LearyJavad NazarianMarcel KoolPieter WesselingMarina RyzhovaOlga ZheludkovaAndrey V GolanovRoger E McLendonRoger J PackerChristopher DunhamJuliette HukinMaryam FouladiClaudia C FariaJose PimentelAndrew W WalterNada JabadoYoon-Jae ChoSebastien PerreaultSidney E CroulMichal ZapotockyCynthia HawkinsUri TaboriMichael D TaylorStefan M PfisterPaul KlimoFrederick A BoopDavid W EllisonThomas E MerchantArzu Onar-ThomasAndrey KorshunovDavid T W JonesAmar J GajjarVijay RamsawamiPaul A NorthcottPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Clinical behavior of relapsed medulloblastoma must be contextualized in terms of up-front therapies and molecular classifications. Group 4 tumors exhibit slower biological progression. Utility of radiation at relapse is dependent on patient age and prior treatments. Degree and patterns of molecular conservation at relapse vary by subgroup. Relapse tissue enables verification of molecular targets and identification of occult secondary malignancies.